Extended-Spectrum Beta-Lactamases Producing Escherichia coli in South America: A Systematic Review with a One Health Perspective
Carlos Bastidas-Caldes,Daniel Romero-Alvarez,Victor Valdez-Vélez,Roberto D Morales,Andrés Montalvo-Hernández,Cicero Gomes-Dias,Manuel Calvopiña
DOI: https://doi.org/10.2147/IDR.S371845
2022-10-01
Infection and Drug Resistance
Abstract:Carlos Bastidas-Caldes, 1, 2 Daniel Romero-Alvarez, 3, 4 Victor Valdez-Vélez, 1 Roberto D Morales, 1 Andrés Montalvo-Hernández, 1 Cicero Gomes-Dias, 5 Manuel Calvopiña 3 1 One Health Research Group, Faculty of Engineering and Applied Sciences, Universidad de las Américas, Quito, Ecuador; 2 Doctoral Program in Public and Animal Health, Faculty of Veterinary Medicine, University of Extremadura, Cáceres, Spain; 3 One Health Reserch Group, Faculty of Medicine, Universidad de las Américas, Quito, Ecuador; 4 Biodiversity Institute and Department of Ecology & Evolutionary Biology, The University of Kansas, Lawrence, KS, USA; 5 Department of Basic Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil Correspondence: Carlos Bastidas-Caldes, One Health Research Group, Faculty of Engineering and Applied Sciences, Universidad de las Américas, Quito, 170124, Ecuador, Tel +593 983 174949, Email Purpose: Extended-spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae, which includes Escherichia coli , has emerged as a global health threat. ESBL enzymes including CTX-M, TEM, and SHV are the most detected. Here, a systematic review was developed to assess the status of ESBLs in E. coli considering studies performed in the human, animal, food, and environmental realms in South America. Methods: Following PRISMA guidelines, a systematic review was performed using the PubMed database as a primary source to identify studies containing data on ESBL-producing E. coli in South America. To obtain a comprehensive sample, studies in English, Spanish, and Portuguese were included from 1990 to April 2021. Inclusion such as the reporting of sample origin and diagnostic method and exclusion criteria such as review/letter articles were established to complete data extraction steps. Results: Amongst 506 articles retrieved, 130 met the inclusion criteria. Brazil reported 65 (50%) of publications, followed by Argentina, and Ecuador with 11.5% each. According to the category of studies, human studies represented the 56%, animals the 20%, environmental the 11%, and food studies the 6%. Interestingly, studies assessing more than one category (ie, interdisciplinary) represented the 7%. Prevalence of ESBL producing E. coli in animal, food, and environmental studies was widely superior compared to human sources. In clinical studies, Brazil presented the greatest diversity in terms of ESBLs, featuring CTX-M, TEM, SHV, TOHO, OXA, and AmpC. CTX-M enzymes were the most frequent variants with 89.4% detections. Conclusion: The present One Health review of 130 studies conducted over the past 21 years found ESBLs producing E. coli distributed across human, animal, food, and environmental samples across South America. There is a need to increment studies in underrepresented countries and to strengthen multi-sectoral antimicrobial resistance research and surveillance. This information can be used as basis for subsequent implementation of monitoring programs, targeting potential critical points of transmission sources. Keywords: extended-spectrum beta-lactamase, Escherichia coli , South America, One Health The antimicrobial resistance phenomena existed long time before humans were implementing antibiotics. 1 Bacteria have several mechanisms to evade the action of antimicrobials. One of the most important in humans, animals, and the environment is the enzyme-mediated breaking of the beta-lactam ring of penicillin and its derivatives. Penicillins are the widest group of antibiotics. 2 Enzyme-mediated resistance is a worldwide public health problem recognized by the World Health Organization (WHO) due to its rapid expansion and the generation of multidrug-resistant (MDR) bacteria that are increasingly difficult to eliminate. 3,4 The current increase and dispersion of penicillin, carbapenem, and cephalosporin resistance is driven by a group of enzymes known as beta-lactamases. These enzymes, commonly found in well-known human environments, have been discovered in apparently unsuitable localities such as soils or glaciers in Antarctica, which have probably never encountered beta-lactam antibiotics previously. 5 Beta-lactamases enzymes were first described in 1940, England; isolated from an E. coli , which prompted antibiotic resistance research. 6,7 In early 1980s, TEM-1, TEM-2 (isolated from a patient in Temoneira in Athens, Greece), and SHV-1 (sulfhydryl variable, active site) circulating beta-lactamases were found capable to hydrolyze the beta-lactamic ring of cephalosporins 8< -Abstract Truncated-
pharmacology & pharmacy,infectious diseases